The objective of this study was to investigate the efficacy and safety of @entity2847 (BRC) as an adjunct to conventional treatment in @entity1252 ( @entity1252 ). A prospective, double-blind, randomized, placebo-controlled study compared BRC at a fixed daily dosage of 2.5 mg with placebo. @entity1 were followed for 2-17 months (mean 12.5 months). Disease activity was assessed using the @entity1252 Disease Activity Index (SLEDAI), numbers of flares were recorded, and serum @entity4090 (PRL) levels were obtained at intervals during the study. @entity1 were allowed to take @entity229 and immunosuppressive drugs. Sixty-six @entity1 with @entity1252 entered the study. Thirty-six were treated with BRC, and 30 controls received placebo. Sixteen @entity1 were removed from the study during the treatment period: five in each group left the study because of adverse effects, five became pregnant, and one @entity1 who took placebo died with @entity12319 . Four @entity1 in the BRC treatment group and three @entity1 in the placebo group moved away or stopped coming for study visits for unknown reasons, and were lost to follow-up during the course. At entry, serum PRL was (mean+/-s.d.) 24.8 ng/ml+/-18.4 in the BRC treatment group. This value fell to 5.8+/-9.0 after 12 months of treatment. Corresponding PRL values in controls were 23.7+/-22.1 pretreatment and 20.3+/-14 after 12 months. PRL levels in BRC-treated subjects were significantly lower than levels in control subjects after 3, 6, 9, and 12 months of treatment. The SLEDAI score on the fifth protocol visit was decreased significantly in the BRC group vs controls: 0.9+/-1.4 vs 2.6+/-4.5 (P < 0.05). Although the absolute number of flares in each group was similar, the mean number of flares/ @entity1 /month was decreased significantly in the BRC group compared to the control group (0.08+/-0.1 vs 0.18+/-0.2, P = 0.03). Long term treatment with a low dose of BRC appears to be a safe and effective means of decreasing @entity1252 flares in @entity1252 @entity1 .

XXXX in @entity1252 : a double-blind, randomized, placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity4090 :: ('5617', 'Gene') :: ['prolactin'] @entity12319 :: ('MESH:D020945', 'Disease') :: ['central nervous system lupus']
@entity2847 :: (MESH:D001971,Chemical) :: ['Bromocriptine']
